The company's net profit was at Rs 1,182 crore, with revenue at Rs 5,633 crore and EBITDA margin rising to 26.7 percent, in ...

ICICI Securities recommended hold rating on Zydus Lifesciences with a target price of Rs 910 in its research report dated May ...

Zydus Lifesciences Q4 stuns with margin guidance, but brokerages trim targets — stock ends at Rs 890. Should you follow ...

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

Results: Net profit for the quarter fell 1% from the year-ago period to ₹1,171 crore. The company reported a one-time loss of ...

Zydus Lifesciences is on analysts' radar. The stock rose nearly 2% on Wednesday after reporting mixed fourth-quarter results.

Zydus Lifesciences Limited announced a notable 19% increase in revenue for FY25, with net profits rising to Rs. 47,451 mn.

Zydus Lifesciences Limited reported a significant 19% increase in revenue for FY25, reaching Rs. 2,32,415 million. The ...

The consolidated net profit of Zydus Lifesciences Ltd for the fourth quarter of financial year 2025 dropped marginally to ...

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...

Multinational pharmaceutical company Zydus Lifesciences Limited on Tuesday reported a 0.96 per cent decline in net profit to ...